Abstract
The metabotropic glutamate 1 receptors (mGluR1) have been shown to play a role in neuropathic pain and neurological and psychiatric disorders such as ischemia, epilepsy, anxiety, as well as schizophrenia and other cognitionrelated disorders. As a result, mGluR1 has been an important target for drug development. As a radiotracer-based in vivo imaging technique Positron Emission Tomography (PET) is an important tool in the investigation of receptor function in the living brain under normal conditions and its dysfunction in diseases, as well as in the study of receptor occupancy by experimental therapeutic agents. In this report we review the development and evaluation of PET radiotracers for mGluR1 and provide an assessment of the tracers that are likely to succeed in the imaging and quantification of mGluR1 in humans.
Keywords: Metabotropic glutamate receptor, mGlu1, radioligand, positron emission tomography, synthesis, evaluation.
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
74